| Farewell, Xconomy Readers. I’m Going to Climb a New Mountain | Luke Timmerman | 03/05/14 | National |
| PacBio, the Post-Hype Sleeper of Genomics | Luke Timmerman | 03/03/14 | National |
| Hiring in Biotech is Tricky. But Algorithms Won’t Save the Day | Luke Timmerman | 02/24/14 | National |
| San Diego Life Sciences Roundup: Lithera, CardioCell, and More | Bruce V. Bigelow | 02/21/14 | San Diego |
| Molecular Diagnostics Are in a Rut. The Industry Needs the FDA | Luke Timmerman | 02/17/14 | National |
| The Young and Proven Biotech VCs From 2012. Where Are They Now? | Luke Timmerman | 02/10/14 | National |
| The $1K Genome? So What? Illumina Is On a Quest for World Domination | Luke Timmerman | 02/03/14 | National |
| Gene Therapy Lurches Ahead, Sees Thorny Future Questions on Price | Luke Timmerman | 01/27/14 | National |
| The Big Guys Have Lost Their Iron Grip, and It’s All Good | Luke Timmerman | 01/20/14 | National |
| What Biotech Pros Will Be Chirping About at JP Morgan This Week | Luke Timmerman | 01/13/14 | National |
| Josh Boger Finds Beauty Off the Coast of Fiji, in Life After Vertex | Luke Timmerman | 01/06/14 | National |
| 10 Tips for Maximizing the JP Morgan Healthcare Experience | Luke Timmerman | 12/23/13 | National |
| What Was Hyped, and What Fell Out of Favor, This Year in Biotech | Luke Timmerman | 12/16/13 | National |
| 12 Things the Pharma Industry Can Do to Rebuild Real Public Trust | Luke Timmerman | 12/09/13 | National |
| 3 Life Sciences Companies That Are Built to Last | Luke Timmerman | 12/02/13 | National |
| Gates Foundation Health Chief on Coaxing Pharma to Do Good (Part 2) | Luke Timmerman | 11/26/13 | National |
| Gates Foundation Health Chief on Coaxing Pharma to Do Good | Luke Timmerman | 11/25/13 | National |
| The Biotech Startup Class of 2013: Don’t Worry, It’s a Short List | Luke Timmerman | 11/18/13 | National |
| How Alkermes Survived a Brush With Death | Luke Timmerman | 11/11/13 | National |
| Which Regions Are Churning Out the Most Biotech IPOs? | Luke Timmerman | 11/04/13 | National |
| The Biggest Bargains Pharma Scooped Up in the Down Years | Luke Timmerman | 10/28/13 | National |
| 21 Red Flags to Watch for in a Biotech Company | Luke Timmerman | 10/21/13 | National |
| The $100M Club: Where the Major League Life Sciences Companies Are | Luke Timmerman | 10/14/13 | National |
| Harvard’s Verdine Blazing Trail for Scientific Entrepreneurs | Luke Timmerman | 10/07/13 | National |
| The Pharma Bureaucracy Index: Who’s Nimble, and Who’s Sloooowww? | Luke Timmerman | 09/30/13 | National |
| The Best Biotech Graduate Schools in Real Life | Luke Timmerman | 09/23/13 | National |
| Don’t Be Naïve: 7 Things to Know Before Taking a Biotech Startup Job | Luke Timmerman | 09/16/13 | National |
| Which VCs Are Poised to Profit From the Biotech IPO Boom? | Luke Timmerman | 09/09/13 | National |
| Biotech and Fantasy Football Picks for Fall 2013 | Luke Timmerman | 09/03/13 | National |
| Why Good Drugs Sometimes Fail: The Bexxar Story | Luke Timmerman | 08/26/13 | National |
